logo-loader
viewBraveheart Investment Group

Braveheart expects Paraytec's second round of trials to start early in 2020

Paraytec is part of an Innovate UK funded R&D project (NEXUS) that includes Malvern Panalytical, the University of Central Lancashire, GSK, Medimmune and Fujifilm Diosynth.

Braveheart Investment Group - Braveheart expects Paraytec's second round of trials to start early in 2020
Paraytec is pioneering the use of UV light detection to measure protein aggregation in biopharmaceuticals

Braveheart Investment Group PLC (LON:BRH) expects wholly-owned subsidiary Paraytec to start the second round of user trials early in 2020.

Paraytec is pioneering the use of UV light detection to measure protein aggregation in biopharmaceuticals and is part of an Innovate UK funded R&D project (NEXUS) that includes Malvern Panalytical, the University of Central Lancashire, GSK, Medimmune and Fujifilm Diosynth.

Aggregates are an impurity that must be controlled and must stay within product specifications, so measurement is essential to ensure they meet the requirements of regulatory agencies said Braveheartm which has updated on the other constituents of its portfolio of six core companies.

Plant nutrients firm Pharm 2 Farm (Braveheart 33.33%) is bidding to get some of the £90mln Innovate UK grant funding available to help agritech businesses.

Biotechnology company Kirkstall (64.67%) is involved with the €4.7 million Horizon 2020 project developing techniques to grow human organs by using light to modify the growth of cells.

Kirkstall is providing specialist Quasi-Vivo products in which the cell cultures will be grown.

Gyrometric Systems (19.95%) has developed shaft monitoring and measurement systems for revolutions as low as 0.25 revolutions per minute, which is useful for wind turbines.

Its ship drive monitoring systems, meanwhile, will be exhibited next year in September at SMM Hamburg, the world's largest exhibition for ship technology.

Phasefocus Holdings (21.20%) ha recently been granted a new US patent for a fundamental improvement in its underlying ptychography imaging technology.

The method protected by the new patent has the potential to speed up Phasefocus's systems by a factor of 10 times.

Sentinel Medical (38.40%) is to revise the trial protocols for its prototype instrument to detect bladder cancer from urine after initial work at Sheffield University.

Quick facts: Braveheart Investment Group

Price: 10.5 GBX

AIM:BRH
Market: AIM
Market Cap: £2.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Braveheart Investment Group named herein, including the promotion by the Company of Braveheart Investment Group in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Braveheart's Trevor Brown details investment in 'exciting' Pharm2Farm Limited

Proactive London's Andrew Scott speaks to Braveheart Investment Group PLC's (LON:BRH) and Pharm2Farm Limited's (P2F) Gareth Cave following Braveheart's investment in the business. P2F has developed a patented process to increase the bioavailability of trace minerals in plant feeds for...

on 15/7/19

2 min read